Frankfurt - Delayed Quote EUR

ACADIA Pharmaceuticals Inc. (DR6.F)

13.02

+0.26

+(2.04%)

At close: April 25 at 8:54:38 AM GMT+2

Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2025

SAN DIEGO, April 23, 2025--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter financial results on Wednesday, May 7, 2025, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on May 7, 2025, at 4:30 p.m. Eastern Time.

Business Wire 2 days ago

ACAD
Declining Stock and Solid Fundamentals: Is The Market Wrong About ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)?

ACADIA Pharmaceuticals (NASDAQ:ACAD) has had a rough three months with its share price down 19%. However, stock prices...

Simply Wall St. 13 days ago

ACAD
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, April 11, 2025--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on April 3, 2025, the Compensation Committee of Acadia’s Board of Directors (the "Committee") granted inducement awards consisting of non-qualified stock options to purchase 172,637 shares of common stock and 64,791 restricted stock units ("RSUs") to twenty-two new employees under Acadia’s 2024 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ e

Business Wire 14 days ago

ACAD
Is ACADIA Pharmaceuticals Inc. (ACAD) a Promising Biotech Stock According to Wall Street Analysts

We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we are going to look at where ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) stands against other biotech stocks. Biotech Sector Set for Growth Amid Innovation and Investor Interest The biotechnology sector is gaining new momentum with better market […]

Insider Monkey last month

ACAD
Is ACADIA Pharmaceuticals Inc. (ACAD) the Best Nasdaq Stock Under $20 to Buy Now?

We recently published a list of 12 Best Nasdaq Stocks Under $20 to Buy Now. In this article, we are going to take a look at where ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) stands against other best Nasdaq stocks under $20 to buy now. The Nasdaq has had a challenging start to 2025, with the index dropping […]

Insider Monkey last month

ACAD
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

SAN DIEGO, March 13, 2025--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in the following virtual investor conferences:

Business Wire last month

ACAD
Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med

SAN DIEGO, March 05, 2025--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the journal Med published results from the open-label study, DAFFODIL™, evaluating the safety, tolerability and exploratory efficacy of DAYBUE® (trofinetide) in girls ages two to four living with Rett syndrome (n = 15). The long-term Phase 2/3 study demonstrated DAYBUE had a similar safety profile in children two to four years of age as that observed in individuals with Rett syndrome five years of age and

Business Wire last month

ACAD
Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates (Revised)

Acadia (ACAD) delivered earnings and revenue surprises of -10.53% and 1.79%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

ACAD
Acadia's Q4 Earnings Miss, Nuplazid & Daybue Drive Revenue Growth (Revised)

ACAD reports mixed fourth-quarter results as earnings missed estimates while revenues beat the same, driven by year-over-year growth in Nuplazid and Daybue sales.

Zacks last month

ACAD
ACADIA Pharmaceuticals Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

ACADIA Pharmaceuticals ( NASDAQ:ACAD ) Full Year 2024 Results Key Financial Results Revenue: US$957.8m (up 32% from FY...

Simply Wall St. last month

ACAD
Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study

SAN DIEGO & COPENHAGEN, Denmark, March 03, 2025--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) and Saniona (OMX: SANION) today announced the successful completion of the two originally planned cohorts in their Phase 1 multiple-ascending-dose MAD study (EUCT: 2024-514514-12-00) of ACP-711, formerly SAN711, in healthy volunteers.

Business Wire last month

SANION.ST

ACAD
ACADIA Pharmaceuticals Inc (ACAD) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ...

ACADIA Pharmaceuticals Inc (ACAD) reports a 32% annual revenue increase, driven by strong sales of DAYBUE and NUPLAZID, while expanding its pipeline and preparing for European market entry.

GuruFocus.com last month

ACAD
Earnings Beat: ACADIA Pharmaceuticals Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) shareholders are probably feeling a little disappointed, since its shares...

Simply Wall St. last month

ACAD
Acadia Pharmaceuticals to Participate in the TD Cowen’s 45th Annual Health Care Conference

SAN DIEGO, February 27, 2025--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at TD Cowen’s 45th Annual Health Care Conference on Wednesday, March 5, 2025 at 11:10 a.m. Eastern Time.

Business Wire last month

ACAD
ACADIA Pharmaceuticals Inc (ACAD) Q4 2024 Earnings Call Highlights: Revenue Surge and Strategic ...

ACADIA Pharmaceuticals Inc (ACAD) reports a 93% revenue growth and strategic acquisitions, despite facing significant net losses and operational challenges.

GuruFocus.com last month

ACAD
Acadia's Q4 Earnings Miss, Nuplazid & Daybue Drive Revenue Growth

ACAD reports mixed fourth-quarter results as earnings missed estimates while revenues beat the same, driven by year-over-year growth in Nuplazid and Daybue sales.

Zacks last month

ACAD
Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates

Acadia (ACAD) delivered earnings and revenue surprises of -10.53% and 1.79%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

ACAD
Acadia: Q4 Earnings Snapshot

SAN DIEGO (AP) — Acadia Pharmaceuticals Inc. ACAD) on Wednesday reported fourth-quarter net income of $143.7 million. The San Diego-based company said it had net income of 86 cents per share.

Associated Press Finance last month

ACAD
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

SAN DIEGO, February 26, 2025--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the fourth quarter and full year ended December 31, 2024.

Business Wire last month

ACAD
Is the Options Market Predicting a Spike in ACADIA Pharmaceuticals (ACAD) Stock?

Investors need to pay close attention to ACADIA Pharmaceuticals (ACAD) stock based on the movements in the options market lately.

Zacks 2 months ago

ACAD

Performance Overview

Return	DR6.F	S&P 500 (^GSPC)
YTD	-19.12%	-6.06%
1-Year	-14.81%	+9.44%
3-Year	-33.23%	+28.61%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

ACADIA Pharmaceuticals Inc. (DR6.F)

Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2025

Declining Stock and Solid Fundamentals: Is The Market Wrong About ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)?

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Is ACADIA Pharmaceuticals Inc. (ACAD) a Promising Biotech Stock According to Wall Street Analysts

Is ACADIA Pharmaceuticals Inc. (ACAD) the Best Nasdaq Stock Under $20 to Buy Now?

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med

Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates (Revised)

Acadia's Q4 Earnings Miss, Nuplazid & Daybue Drive Revenue Growth (Revised)

ACADIA Pharmaceuticals Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study

ACADIA Pharmaceuticals Inc (ACAD) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ...

Earnings Beat: ACADIA Pharmaceuticals Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Acadia Pharmaceuticals to Participate in the TD Cowen’s 45th Annual Health Care Conference

ACADIA Pharmaceuticals Inc (ACAD) Q4 2024 Earnings Call Highlights: Revenue Surge and Strategic ...

Acadia's Q4 Earnings Miss, Nuplazid & Daybue Drive Revenue Growth

Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates

Acadia: Q4 Earnings Snapshot

Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

Is the Options Market Predicting a Spike in ACADIA Pharmaceuticals (ACAD) Stock?

Performance Overview